Tesamorelin
A growth-hormone-releasing hormone analog studied for visceral fat
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). It has been studied for reducing excess visceral abdominal fat and supporting body composition. Through Madison Meds, tesamorelin is available after a licensed-provider evaluation, with the medication dispensed by a US-licensed compounding pharmacy.
From $189/mo
3-Month $627 ($209/mo) | 6-Month $1,134 ($189/mo) | Available after a licensed-provider evaluation
Frequency
Daily subcutaneous
Rx Required
Yes, Prescribed Online
Pharmacy
US-Registered
Shipping
Free & Discreet
Tesamorelin at a Glance
What is tesamorelin? Tesamorelin is a synthetic 44-amino-acid analog of growth-hormone-releasing hormone (GHRH). It stimulates the body's own release of growth hormone from the pituitary gland.
What is tesamorelin used for? Tesamorelin is FDA approved under the brand Egrifta to reduce excess abdominal fat in people with HIV-associated lipodystrophy. It has also been studied more broadly for visceral fat and body composition.
How is tesamorelin taken? Tesamorelin is given as a daily subcutaneous injection. A licensed provider sets your dose and monitors your response over time.
How Tesamorelin Works
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone, a 44-amino-acid peptide. Rather than supplying growth hormone directly, it prompts the pituitary gland to release the body's own growth hormone in a more natural, pulsatile pattern.
Increased growth-hormone signaling has been studied for its effect on lipolysis, the breakdown of stored fat, with particular research attention on visceral adipose tissue, the deeper abdominal fat that surrounds internal organs. The branded product Egrifta is FDA approved to reduce excess abdominal fat in people with HIV-associated lipodystrophy. Compounded tesamorelin offered through Madison Meds is a separate compounded preparation and is not the branded product.
Tesamorelin may be considered for eligible patients after a licensed-provider evaluation. Because it affects growth-hormone signaling, your provider will review your medical history and may monitor blood-sugar and IGF-1 levels during treatment.
What Tesamorelin is studied for
Visceral fat focus
Studied in research for its effect on deep abdominal (visceral) fat around the internal organs.
Natural GH release
Prompts the pituitary to release the body's own growth hormone in a pulsatile pattern.
Body composition
Examined for its influence on the ratio of lean mass to fat mass over time.
FDA-approved active
The active tesamorelin is the approved ingredient in the branded product Egrifta for a specific indication.
Metabolic research
Studied beyond its approved use for general visceral adiposity and related metabolic markers.
Provider-monitored
Dose and monitoring, including relevant labs, are directed by a licensed provider.
What to Expect
Complete your online intake
Answer a short set of health questions so an independent, US-licensed provider can review whether tesamorelin is appropriate for you.
Provider review
A licensed provider from an independent network evaluates your intake and, if appropriate, authorizes a personalized protocol and any recommended lab monitoring.
Discreet delivery
If eligible, your medication is dispensed by a US-licensed compounding pharmacy and shipped directly to your door with free, discreet shipping.
Compounding Notice
Tesamorelin offered through Madison Meds is a compounded preparation prepared by a US-licensed compounding pharmacy. Compounded products are not reviewed by the FDA for safety or effectiveness and are prepared for an individual patient pursuant to a valid prescription. The FDA-approved tesamorelin product Egrifta is a separate, branded medication with a specific approved indication. Use only under the ongoing supervision of a licensed healthcare provider. Learn more about compounded medications under section 503A.
Important Safety Information
Tesamorelin affects growth-hormone signaling and is not appropriate for everyone. It should not be used by people with active cancer, certain pituitary conditions, or during pregnancy or breastfeeding. Share your full medical history with your provider.
Because it can affect blood sugar and IGF-1 levels, your provider may recommend periodic lab monitoring. Report side effects such as joint pain, swelling, injection-site reactions, or changes in blood sugar to your provider.
Do not start tesamorelin without a licensed-provider evaluation. This is educational content and not medical advice. Individual results vary. Seek prompt medical attention for any severe or unexpected reaction.
Ready to take the next step?
See whether tesamorelin fits your body-composition goals. Complete a short online intake and a licensed provider will review your eligibility.
FAQ
Tesamorelin questions, answered
Educational content. Not medical advice. Individual results vary. Prescription therapies are available only after a licensed-provider evaluation. Medications are dispensed by a US-licensed compounding pharmacy. Talk with a licensed provider before starting or stopping any medication or supplement. See our Compounded Medication Disclosure, Telehealth Disclosure, and Medication Risks.